3.4.23.B24: signal peptide peptidase
This is an abbreviated version!
For detailed information about signal peptide peptidase, go to the full flat file.
Word Map on EC 3.4.23.B24
-
3.4.23.B24
-
aspartyl
-
presenilins
-
intramembrane-cleaving
-
gamma-secretase
-
sppl2a
-
medicine
-
gxgd-type
-
spp-mediated
-
bri2
-
i-clips
-
presenilin-like
-
site-2
-
pharmacology
-
analysis
- 3.4.23.B24
-
aspartyl
-
presenilins
-
intramembrane-cleaving
- gamma-secretase
- sppl2a
- medicine
-
gxgd-type
-
spp-mediated
- bri2
- i-clips
-
presenilin-like
-
site-2
- pharmacology
- analysis
Reaction
intramembrane cleavage of signal peptides =
Synonyms
ANID_08681, aspartic intramembrane protease, Hm13, hSPP, minor histocompatibility antigen H13, PF3D7_1457000, PlSPP, signal peptide peptidase like 2a, signal peptide peptidase-like 2a, signal peptide peptidase-like 2B, signal peptide peptidase-like 2C, signal peptide peptidase-like 3, SPP, SPP-like 2A, SPP-like 2B, SPP-like 2C, SPP-like 3, SPP1, SppA, SPPL, SPPL2a, SPPL2b, SPPL2c, UMAG_02729
ECTree
Advanced search results
Inhibitors
Inhibitors on EC 3.4.23.B24 - signal peptide peptidase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
(2R)-2-methyl-N1-[(10S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]-N4-[2-(trifluoromethyl)phenyl]butanediamide
-
-
(2R)-2-methyl-N4-(2-methylphenyl)-N1-[(10S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]butanediamide
-
(2R)-2-methyl-N4-(2-methylpyridin-3-yl)-N1-[(10S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]butanediamide
-
-
(2R)-2-methyl-N4-(3-methylphenyl)-N1-[(10S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]butanediamide
-
-
(2R)-2-methyl-N4-(4-methylphenyl)-N1-[(10S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]butanediamide
-
-
(2R)-N1-[(10S)-5,11-dioxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]-N4-(5-fluoro-2-methylpyridin-3-yl)-2-methylbutanediamide
-
-
(2R)-N4-(3,5-difluorophenyl)-2-methyl-N1-[(10S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]butanediamide
-
-
(2R)-N4-(5-fluoro-2-methylpyridin-3-yl)-2-methyl-N1-[(10S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]butanediamide
-
(2R)-N4-(5-fluoro-2-methylpyridin-3-yl)-N1-[(10S)-6-fluoro-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]-2-methylbutanediamide
-
(2S)-2-cyclopropyl-N1-[(10'S)-5',11'-dioxo-10',11'-dihydro-1'H,3'H,5'H-spiro[cyclopropane-1,2'-pyrazolo[1,2-b][2,3]benzodiazepin]-10'-yl]-N4-(5-fluoro-2-methylpyridin-3-yl)butanediamide
-
(2S)-2-cyclopropyl-N1-[(10'S)-5',11'-dioxo-10',11'-dihydro-5'H-spiro[cyclopropane-1,2'-pyrazolo[1,2-b][2,3]benzodiazepin]-10'-yl]-N4-(5-fluoro-2-methylpyridin-3-yl)butanediamide
-
(2S)-2-cyclopropyl-N1-[(10S)-5,11-dioxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]-N4-(5-fluoro-2-methylpyridin-3-yl)butanediamide
-
-
(S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide
LY-411575
N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide
N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide
NH3-SPRMMYLYAK-COOH
peptide synthesized corresponding to the sequence of the modeled C-terminal peptide bound in the SppA substrate-binding groove. Competitive inhibition
[(2R,4R,5S)-2-benzyl-5-(t-butyloxycarbonylamino)-4-hydroxy-6-phenylhexanoyl]-L-leucyl-L-phenylalanine amide
(2R)-2-methyl-N4-(2-methylphenyl)-N1-[(10S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]butanediamide
reversible, inhibits CD74/p8 processing in vivo and spares gamma-secretase activity
-
(2R)-2-methyl-N4-(2-methylphenyl)-N1-[(10S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]butanediamide
-
-
(2R)-2-methyl-N4-(2-methylphenyl)-N1-[(10S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]butanediamide
-
-
(2R)-N4-(5-fluoro-2-methylpyridin-3-yl)-2-methyl-N1-[(10S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]butanediamide
-
-
(2R)-N4-(5-fluoro-2-methylpyridin-3-yl)-2-methyl-N1-[(10S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]butanediamide
-
-
(2R)-N4-(5-fluoro-2-methylpyridin-3-yl)-2-methyl-N1-[(10S)-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]butanediamide
-
-
(2R)-N4-(5-fluoro-2-methylpyridin-3-yl)-N1-[(10S)-6-fluoro-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]-2-methylbutanediamide
-
-
(2R)-N4-(5-fluoro-2-methylpyridin-3-yl)-N1-[(10S)-6-fluoro-11-oxo-2,3,10,11-tetrahydro-1H,5H-pyrazolo[1,2-b][2,3]benzodiazepin-10-yl]-2-methylbutanediamide
-
-
(2S)-2-cyclopropyl-N1-[(10'S)-5',11'-dioxo-10',11'-dihydro-5'H-spiro[cyclopropane-1,2'-pyrazolo[1,2-b][2,3]benzodiazepin]-10'-yl]-N4-(5-fluoro-2-methylpyridin-3-yl)butanediamide
-
-
(2S)-2-cyclopropyl-N1-[(10'S)-5',11'-dioxo-10',11'-dihydro-5'H-spiro[cyclopropane-1,2'-pyrazolo[1,2-b][2,3]benzodiazepin]-10'-yl]-N4-(5-fluoro-2-methylpyridin-3-yl)butanediamide
-
-
(2S)-2-cyclopropyl-N1-[(10'S)-5',11'-dioxo-10',11'-dihydro-5'H-spiro[cyclopropane-1,2'-pyrazolo[1,2-b][2,3]benzodiazepin]-10'-yl]-N4-(5-fluoro-2-methylpyridin-3-yl)butanediamide
-
-
(S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide
-
i.e. Compound E
(S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide
-
i.e. Compound E, below 50% inhibition
signal peptide peptidase specific inhibitor
-
i.e. (Z-LL)2 ketone
2,2'-(2-oxo-1,3-propanediyl)bis[N-[(phenylmethoxy)carbonyl]-L-leucyl-L-leucinamide]
(Z-LL)2-ketone
2,2'-(2-oxo-1,3-propanediyl)bis[N-[(phenylmethoxy)carbonyl]-L-leucyl-L-leucinamide]
-
i.e. (Z-LL)2 ketone, causes over 75% inhibition of FBA cleavage at 0.01 mM
2,2'-(2-oxo-1,3-propanediyl)bis[N-[(phenylmethoxy)carbonyl]-L-leucyl-L-leucinamide]
-
i.e. (Z-LL)2 ketone
2,2'-(2-oxo-1,3-propanediyl)bis[N-[(phenylmethoxy)carbonyl]-L-leucyl-L-leucinamide]
(Z-LL)2-ketone; (Z-LL)2-ketone; (Z-LL)2-ketone
2,2'-(2-oxo-1,3-propanediyl)bis[N-[(phenylmethoxy)carbonyl]-L-leucyl-L-leucinamide]
(Z-LL)2-ketone
2,2'-(2-oxo-1,3-propanediyl)bis[N-[(phenylmethoxy)carbonyl]-L-leucyl-L-leucinamide]
-
i.e. (Z-LL)2 ketone, causes over 75% inhibition of FBA cleavage at 0.01 mM
2,2'-(2-oxo-1,3-propanediyl)bis[N-[(phenylmethoxy)carbonyl]-L-leucyl-L-leucinamide]
-
i.e. (Z-LL)2 ketone, causes over 75% inhibition of FBA cleavage at 0.01 mM
2,2'-(2-oxo-1,3-propanediyl)bis[N-[(phenylmethoxy)carbonyl]-L-leucyl-L-leucinamide]
(Z-LL)2-ketone
N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide
-
i.e. DBZ
N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide
DBZ; DBZ
[(2R,4R,5S)-2-benzyl-5-(t-butyloxycarbonylamino)-4-hydroxy-6-phenylhexanoyl]-L-leucyl-L-phenylalanine amide
aspartic protease inhibitor that targets signal peptide peptidase or presenilin
[(2R,4R,5S)-2-benzyl-5-(t-butyloxycarbonylamino)-4-hydroxy-6-phenylhexanoyl]-L-leucyl-L-phenylalanine amide
-
-
increasing the rigidity of the transmembrane helices prevents SPP-catalyzed cleavage
-
additional information
development and synthesis of potent, selective, and orally bioavailable signal peptide peptidase-like 2a (SPPL2a) inhibitors displaying pronounced immunomodulatory effects in vivo. Selectivity of inhibitors for SPP compared to gamma-secretase, overview
-
additional information
SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by 2,2'-(2-oxo-1,3-propanediyl)bis[N-[(phenylmethoxy)carbonyl]-L-leucyl-L-leucinamide] ((Z-LL)2-ketone), L-685,458, and N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT); SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT), N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide (DBZ), and (S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide (Compound E); SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT), semagacestat, avagacestat, and MK-0752; SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT), weak inhibition by (S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide (Compound E) and N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide (DBZ)
-
additional information
SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by 2,2'-(2-oxo-1,3-propanediyl)bis[N-[(phenylmethoxy)carbonyl]-L-leucyl-L-leucinamide] ((Z-LL)2-ketone), L-685,458, and N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT); SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT), N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide (DBZ), and (S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide (Compound E); SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT), semagacestat, avagacestat, and MK-0752; SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT), weak inhibition by (S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide (Compound E) and N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide (DBZ)
-
additional information
SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by 2,2'-(2-oxo-1,3-propanediyl)bis[N-[(phenylmethoxy)carbonyl]-L-leucyl-L-leucinamide] ((Z-LL)2-ketone), L-685,458, and N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT); SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT), N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide (DBZ), and (S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide (Compound E); SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT), semagacestat, avagacestat, and MK-0752; SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT), weak inhibition by (S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide (Compound E) and N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide (DBZ)
-
additional information
SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by 2,2'-(2-oxo-1,3-propanediyl)bis[N-[(phenylmethoxy)carbonyl]-L-leucyl-L-leucinamide] ((Z-LL)2-ketone), L-685,458, and N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT); SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT), N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide (DBZ), and (S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide (Compound E); SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT), semagacestat, avagacestat, and MK-0752; SPP/SPPL proteases employ a catalytic mechanism related to that of the gamma-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and gamma-secretase by inhibitors is demonstrated. No inhibition by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT), weak inhibition by (S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide (Compound E) and N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide (DBZ)
-
additional information
development and synthesis of potent, selective, and orally bioavailable signal peptide peptidase-like 2a (SPPL2a) inhibitor displaying pronounced immunomodulatory effects in vivo. Selectivity of inhibitors for SPP compared to gamma-secretase, overview
-
additional information
-
development and synthesis of potent, selective, and orally bioavailable signal peptide peptidase-like 2a (SPPL2a) inhibitor displaying pronounced immunomodulatory effects in vivo. Selectivity of inhibitors for SPP compared to gamma-secretase, overview
-
additional information
-
no inhibition by N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide (DBZ); no inhibition by (S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide (Compound E) and N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide (DBZ)
-
additional information
inhibition of Plasmodium SPP (PlSPP) can be of clinical relevance for fighting malaria infections. SPP inhibitors for Plasmodium block SPP. SPP-mediated proteolysis might cause endoplasmic reticulum stress leading to an altered Plasmodium life cycle and growth inhibition. The developmental stage of Plasmodium is affected by PlSPP inhibition
-
additional information
-
no inhibition by (S,S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide (Compound E) and N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide (DBZ)
-
additional information
development and synthesis of potent, selective, and orally bioavailable signal peptide peptidase-like 2a (SPPL2a) inhibitor displaying pronounced immunomodulatory effects in vivo. Seletivity of inhibitors for SPP compared to gamma-secretase, overview
-